CAPRICOR THERAPEUTICS INC (CAPR)

US14070B3096 - Common Stock

13.07  +0.17 (+1.32%)

After market: 13.24 +0.17 (+1.3%)

Fundamental Rating

3

CAPR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. CAPR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CAPR is valued quite expensively, but it does show have an excellent growth rating.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CAPR has reported negative net income.
In the past year CAPR has reported a negative cash flow from operations.
CAPR had negative earnings in each of the past 5 years.
In the past 5 years CAPR reported 4 times negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -36.70%, CAPR is in the better half of the industry, outperforming 60.53% of the companies in the same industry.
CAPR has a Return On Equity of -49.97%. This is in the better half of the industry: CAPR outperforms 67.26% of its industry peers.
Industry RankSector Rank
ROA -36.7%
ROE -49.97%
ROIC N/A
ROA(3y)-48.11%
ROA(5y)-50.51%
ROE(3y)-136.19%
ROE(5y)-113.74%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CAPR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

CAPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
CAPR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CAPR has been increased compared to 5 years ago.
Compared to 1 year ago, CAPR has an improved debt to assets ratio.

2.2 Solvency

An Altman-Z score of 11.16 indicates that CAPR is not in any danger for bankruptcy at the moment.
CAPR has a Altman-Z score of 11.16. This is amongst the best in the industry. CAPR outperforms 87.61% of its industry peers.
CAPR has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
CAPR's Debt to Equity ratio of 0.05 is on the low side compared to the rest of the industry. CAPR is outperformed by 61.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 11.16
ROIC/WACCN/A
WACC11.9%

2.3 Liquidity

CAPR has a Current Ratio of 4.19. This indicates that CAPR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.19, CAPR is in line with its industry, outperforming 48.50% of the companies in the same industry.
CAPR has a Quick Ratio of 4.19. This indicates that CAPR is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.19, CAPR perfoms like the industry average, outperforming 50.09% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.19
Quick Ratio 4.19

More info and screens

7

3. Growth

3.1 Past

CAPR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.62%, which is quite good.
CAPR shows a strong growth in Revenue. In the last year, the Revenue has grown by 65.21%.
Measured over the past years, CAPR shows a very strong growth in Revenue. The Revenue has been growing by 72.05% on average per year.
EPS 1Y (TTM)8.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52%
Revenue 1Y (TTM)65.21%
Revenue growth 3Y333.07%
Revenue growth 5Y72.05%
Sales Q2Q%-63.43%

3.2 Future

Based on estimates for the next years, CAPR will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.39% on average per year.
Based on estimates for the next years, CAPR will show a very strong growth in Revenue. The Revenue will grow by 69.00% on average per year.
EPS Next Y-67.19%
EPS Next 2Y-6%
EPS Next 3Y42.53%
EPS Next 5Y8.39%
Revenue Next Year-29.79%
Revenue Next 2Y34.45%
Revenue Next 3Y75.63%
Revenue Next 5Y69%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CAPR. In the last year negative earnings were reported.
Also next year CAPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

CAPR's earnings are expected to grow with 42.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6%
EPS Next 3Y42.53%

More info and screens

0

5. Dividend

5.1 Amount

CAPR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAPRICOR THERAPEUTICS INC

NASDAQ:CAPR (12/20/2024, 5:20:01 PM)

After market: 13.24 +0.17 (+1.3%)

13.07

+0.17 (+1.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners18.46%
Inst Owner Change31.48%
Ins Owners33.09%
Ins Owner Change18.83%
Market Cap594.29M
Analysts84.62
Price Target42.11 (222.19%)
Short Float %11.65%
Short Ratio2.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.18%
Min EPS beat(2)-3.97%
Max EPS beat(2)3.61%
EPS beat(4)2
Avg EPS beat(4)-22.58%
Min EPS beat(4)-168.17%
Max EPS beat(4)78.21%
EPS beat(8)6
Avg EPS beat(8)-5.22%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-15.79%
Min Revenue beat(2)-37.86%
Max Revenue beat(2)6.27%
Revenue beat(4)2
Avg Revenue beat(4)-17.55%
Min Revenue beat(4)-50.41%
Max Revenue beat(4)11.8%
Revenue beat(8)6
Avg Revenue beat(8)2423.31%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.7%
PT rev (3m)108.51%
EPS NQ rev (1m)-81.11%
EPS NQ rev (3m)-81.11%
EPS NY rev (1m)-3.78%
EPS NY rev (3m)-6.42%
Revenue NQ rev (1m)-43.72%
Revenue NQ rev (3m)-43.72%
Revenue NY rev (1m)-8.52%
Revenue NY rev (3m)-21.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 25.59
P/FCF N/A
P/OCF N/A
P/B 8.71
P/tB 8.71
EV/EBITDA N/A
EPS(TTM)-1.06
EYN/A
EPS(NY)-0.98
Fwd EYN/A
FCF(TTM)-0.84
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS0.51
BVpS1.5
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.7%
ROE -49.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.11%
ROA(5y)-50.51%
ROE(3y)-136.19%
ROE(5y)-113.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 112.76%
Cap/Sales 6.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.19
Quick Ratio 4.19
Altman-Z 11.16
F-Score4
WACC11.9%
ROIC/WACCN/A
Cap/Depr(3y)435.17%
Cap/Depr(5y)339.68%
Cap/Sales(3y)213.3%
Cap/Sales(5y)163.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52%
EPS Next Y-67.19%
EPS Next 2Y-6%
EPS Next 3Y42.53%
EPS Next 5Y8.39%
Revenue 1Y (TTM)65.21%
Revenue growth 3Y333.07%
Revenue growth 5Y72.05%
Sales Q2Q%-63.43%
Revenue Next Year-29.79%
Revenue Next 2Y34.45%
Revenue Next 3Y75.63%
Revenue Next 5Y69%
EBIT growth 1Y-21.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-66.86%
EBIT Next 3Y18.57%
EBIT Next 5YN/A
FCF growth 1Y-1141.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-694.44%
OCF growth 3YN/A
OCF growth 5YN/A